These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2610501)

  • 1. In vitro and in vivo antibacterial activities of KB-5246, a new tetracyclic quinolone.
    Kotera Y; Mitsuhashi S
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1896-900. PubMed ID: 2610501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
    Hosaka M; Yasue T; Fukuda H; Tomizawa H; Aoyama H; Hirai K
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus.
    Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G
    Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.
    Gargallo-Viola D; Esteve M; Llovera S; Roca X; Guinea J
    Antimicrob Agents Chemother; 1991 Mar; 35(3):442-7. PubMed ID: 2039195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
    Nakamura S; Minami A; Nakata K; Kurobe N; Kouno K; Sakaguchi Y; Kashimoto S; Yoshida H; Kojima T; Ohue T
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1167-73. PubMed ID: 2802544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
    Fukuoka Y; Ikeda Y; Yamashiro Y; Takahata M; Todo Y; Narita H
    Antimicrob Agents Chemother; 1993 Mar; 37(3):384-92. PubMed ID: 8460909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria.
    Wakebe H; Mitsuhashi S
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2185-91. PubMed ID: 1332589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
    Yoshida T; Mitsuhashi S
    Antimicrob Agents Chemother; 1993 Apr; 37(4):793-800. PubMed ID: 8388199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria.
    Sedlock DM; Dobson RA; Deuel DM; Lesher GY; Rake JB
    Antimicrob Agents Chemother; 1990 Apr; 34(4):568-75. PubMed ID: 2344163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
    Hirose T; Okezaki E; Kato H; Ito Y; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1987 Jun; 31(6):854-9. PubMed ID: 3476021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo antibacterial efficacies of CFC-222, a new fluoroquinolone.
    Kim JH; Kang JA; Kim YG; Kim JW; Lee JH; Choi EC; Kim BK
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2209-13. PubMed ID: 9333049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
    Smith KR; Cobbs CG
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):55-8. PubMed ID: 1314175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of sparfloxacin compared with those of five other quinolones.
    Cantón E; Pemán J; Jimenez MT; Ramón MS; Gobernado M
    Antimicrob Agents Chemother; 1992 Mar; 36(3):558-65. PubMed ID: 1320362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
    Arpi M; Gahrn-Hansen B; Søgaard P; Bentzon MW
    Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):141-6. PubMed ID: 3473910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
    Bongaerts GP; Hoogkamp-Korstanje JA
    Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.